# Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026

- Link: https://www.thailand-business-news.com/pr-news/likang-life-sciences-showcases-personalized-cancer-immunotherapy-and-global-ambitions-at-abu-dhabi-future-health-summit-2026
- Published: 2026-10-24T18:38:00+07:00
- Author: PR Newswire

BEIJING, Oct. 24, 2026 /PRNewswire/ — Likang Life Sciences ("Likang"), a biotechnology
company advancing AI-enabled personalized cancer immunotherapies, sponsored and 
exhibited at the Abu Dhabi Future Health Summit 2026, held from 20 to 22 October
at ADNEC Centre Abu Dhabi. The summit marked a milestone in Likang’s international
outreach, showcasing its scientific platform and clinical development programs.

Convened by the Department of Health – Abu Dhabi under the theme "To Sense Is to
Predict," the event brought together leaders across healthcare, research and technology.

Likang Co-Founder and Vice Chairman Shannon Cheung joined a delegation of international
health leaders received by UAE President His Highness Sheikh Mohamed bin Zayed Al
Nahyan on 20 October. He also met Abu Dhabi Crown Prince His Highness Sheikh Khaled
bin Mohamed bin Zayed Al Nahyan during his summit visit on 21 October. In brief 
exchanges, Cheung shared Likang’s plans to bring its personalized cancer immunotherapy
technologies and investigational therapies to Abu Dhabi, with a vision to develop
the emirate as a platform for international research, innovation and future expansion.

Cheung spoke on "The Future of Cancer," moderated by Dr. Tarek Fadel of the Massachusetts
Institute of Technology (MIT), alongside Dr. Arie Belldegrun, Chairman of Bellco
Health; Dr. Toni Choueiri of Harvard Medical School and Dana-Farber Cancer Institute;
Prof. Dr. Angela George of The Royal Marsden; and Vinicius Ribeiro, CEO of Huna.

"The future of cancer care is not just about treating cancer earlier, but treating
every patient more precisely, personally and effectively," Cheung said. He discussed
how genomics, AI, mRNA technology and advanced cell manufacturing could support 
therapies tailored to individual tumor biology, while underscoring scalability and
patient access.

At Booth AD28, Likang presented its AI-enabled neoantigen discovery platform and
investigational immunotherapy pipeline. Its lead candidate, LK101, a personalized
neoantigen mRNA-dendritic cell therapeutic cancer vaccine, received clinical trial
authorization from China’s National Medical Products Administration (NMPA) in 2023
and investigational new drug (IND) clearance from the U.S. Food and Drug Administration(
FDA) in 2025.

Building on ongoing dialogue with the Department of Health – Abu Dhabi and regional
healthcare stakeholders, Likang is exploring opportunities in clinical research,
AI-enabled precision oncology, scientific collaboration and potential future local
manufacturing.

**About Likang Life Sciences**

Likang Life Sciences is a biotechnology company focused on AI-powered personalized
cancer immunotherapy. Its pipeline includes personalized neoantigen therapeutic 
vaccines and neoantigen-specific T-cell therapies.

Website: [www.likanglife.com](https://www.likanglife.com/)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026 ](http://www.prnasia.com/story/archive/5080339_AE80339_0?rand=184833)